A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer

NCT05205421 ↗

Phase 1 Unknown 20 enrolled The First Affiliated Hospital of Bengbu Medical University

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.

Timeline

Start: 2022-01-18
Primary completion: 2023-01
Completion: 2024-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RT-01	Other / unclassified	—	Intravenous

Indications

No indication recorded.